©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2024; 15(12): 2380-2383
Published online Dec 15, 2024. doi: 10.4239/wjd.v15.i12.2380
Published online Dec 15, 2024. doi: 10.4239/wjd.v15.i12.2380
Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management
Ke-Xin Zhang, Cheng-Xia Kan, Yu-Qun Wang, Ning-Ning Hou, Xiao-Dong Sun, Department of Endocrinology and Metabolism, The Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China
Author contributions: All the authors contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Xiao-Dong Sun, MD, PhD, Chief Doctor, Department of Endocrinology and Metabolism, The Affiliated Hospital of Shandong Second Medical University, No. 2428 Yuhe Road, Weifang 261031, Shandong Province, China. xiaodong.sun@sdsmu.edu.cn
Received: July 8, 2024
Revised: September 13, 2024
Accepted: October 12, 2024
Published online: December 15, 2024
Processing time: 132 Days and 17.7 Hours
Revised: September 13, 2024
Accepted: October 12, 2024
Published online: December 15, 2024
Processing time: 132 Days and 17.7 Hours
Core Tip
Core Tip: Elevated intestinal glucagon-like peptide-1 impairs hypoglycemic counterregulation in type 1 diabetes by reducing glucagon and adrenaline secretion. This highlights the need for a balanced approach to glucagon-like peptide-1-based therapies, consi